Ultraviolet and visible (UV-Vis) absorption spectroscopy is the measurement of the attenuation of a beamof light after it passes through a sample or after reflection from a sample surface. Light energy is converted by detectors into electrical impulses that are read out by readout devices. The transmitted radiation strikes the detector, determining the amount of radiation absorbed by the sample. The absorption spectrophotometer's apparatus uses the following types of detectors. Aim of the present study is to develop an accurate, precise, sensitive, selectivity, analyticaltechnique to determine the Drospirenone and Estetrol in pharmaceutical dosage forms. Drospirenone is a progestin used in oral contraceptive pills for the prevention of pregnancyand other conditions. Percentage of RSD for intra-day and inter-day precision studies for both drugs were well within the acceptable range (< 2 %) indicating that the method have excellent repeatability and reproducibility

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Decitabine and Cedazuridine was done by RP-HPLC. The Phosphate buffer was pH 4.5 and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of PH 4.5(20:80 v/v). Kromosil C18 Column (250mm x 4.6mm)5µg or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 254 nm. The solutions were chromatographed at a constant flow rate of 1 ml min-1. The linearity range of Decitabine and Cedazuridine were found to be from 100-500 mg/ml of Decitabine and 1-5mg/ml of Cedazuridine. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. Decitabine %RSD 0.2 and Cedazuridine %RSD 0.6. Intermediate precision for Decitabine %RSD 0.2 and Cedazuridine %RSD 0.1 The percentage recovery varies from 98-102% of Decitabine and Cedazuridine. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements .it inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision

Analytical method development and validation plays important role in the discovery, development and manufacture of pharmaceuticals. HPLC mainly utilizes a column that holds packing material (stationary phase), a pump that moves the mobile phase(s) through the column, and a detector that shows the retention times of the molecules. Sitagliptin is used for the treatment of type 2 diabetes mellitus. It is prescribed as an adjunct to diet and exercise to improve glycemic control in adults. Sitagliptin is anti-diabetic drug is more potent inhibitor of DPP-4. The present study was planned to estimate the drug present in the tablets by developing and validating new RP-HPLC method. In chromatographic analysis of substances RP-HPLC is normally advocated because of faster elution. The proposed RP-HPLC methods in construction with dissolution studies were developed for the quantitative estimation of the Sitagliptin was found to be accurate, rapid, sensitive and economical

A new RP-HPLC method was developed and validated for the simultaneous estimation of Vilanterol trifenatate and Fluticasone furoate in bulk and pharmaceutical dosage forms. Chromatographic separation was achieved using a Waters BEH C18 column (4.6×150mm, 5?m), with a mobile phase consisting of methanol:acetonitrile buffer (60:20:20 v/v) at a flow rate of 1.0 ml/min, and detection at 280 nm. Retention times were 3.539 mins for Vilanterol trifenatate and 4.232 mins for Fluticasone furoate. The method exhibited high system suitability parameters, including theoretical plates, tailing factors, and resolution. The method was validated in accordance with ICH guidelines, demonstrating excellent linearity (r2=0.999 for both compounds), accuracy, precision, and robustness. The linearity range was 50?g-250?g for Vilanterol trifenatate and 5?g-25?g for Fluticasone furoate. Percentage recoveries were 99.56% and 99.48%, respectively, with %RSD for repeatability at 0.1 and 1.4. Intermediate precision %RSD for analysts 1 and 2 were within acceptable limits. LOD values were 0.39 ?g/ml and 0.7 ?g/ml, and LOQ values were 1.18 ?g/ml and 2.12 ?g/ml for Vilanterol trifenatate and Fluticasone furoate, respectively. The method was further validated through force degradation studies under various conditions, proving its stability-indicating capability. This RP-HPLC method is suitable for routine quality control, stability studies, and simultaneous analysis of Vilanterol trifenatate and Fluticasone furoate in pharmaceutical formulations

A novel reverse-phase high-performance liquid chromatography (RP-HPLC) method was designed and developed for the simultaneous estimation of Topiroxostat and Dotinurad in synthetic mixtures. The method exhibited high accuracy, precision, and robustness, making it ideal for routine analytical applications. Assay results demonstrated 99.93% for Topiroxostat and 99.95% for Dotinurad, indicating minimal error and reliable quantification of active pharmaceutical ingredients. Linearity assessments revealed a correlation coefficient of 0.999 for both compounds, confirming excellent linearity and sensitivity across a wide concentration range. The method showed remarkable precision with relative standard deviation (RSD) values of 0.6% for Topiroxostat and 0.8% for Dotinurad, well within the acceptance criteria of RSD not more than 2.0%. Intermediate precision, with RSD values of 0.6% for both drugs, demonstrated the method's reliability across different days and analysts. Accuracy was validated through recovery studies, yielding 99.60% for Topiroxostat and 100.15% for Dotinurad, within the acceptable range of 97.0% to 103.0%, indicating reliable recovery of analytes. Limits of detection (LOD) were 3.07 ?g/mL for Topiroxostat and 2.95 ?g/mL for Dotinurad, while limits of quantification (LOQ) were 10.09 ?g/mL and 9.93 ?g/mL, respectively, showcasing the method's capability for trace analysis. Robustness testing confirmed consistent performance under varied mobile phase composition and flow rate conditions. The method's robustness and system suitability, coupled with high precision and accuracy, underscore its potential for routine quality control, dissolution studies, and bioequivalence assessments of formulations containing Topiroxostat and Dotinurad